{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:55:47Z","timestamp":1792284947192,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY18H090012"],"award-info":[{"award-number":["LY18H090012"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019976","name":"Science and Technology Bureau of Jiaxing City","doi-asserted-by":"publisher","award":["2021AY10048"],"award-info":[{"award-number":["2021AY10048"]}],"id":[{"id":"10.13039\/501100019976","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nonalcoholic fatty liver disease (NAFLD) is closely associated with Cardiovascular disease (CVD). We aim to examine the association of Life\u2019s Essential 8 (LE8), the recently updated measurement of cardiovascular health (CVH), with the presence of NAFLD among US adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This population-based cross-sectional study used data from the National Health and Nutrition Examination Survey in 2017\u20132018 and included adults 20\u00a0years or older. LE8 score (range 0\u2013100) was measured according to American Heart Association definitions and was categorized into low (0\u201349), moderate (50\u201379), and high (80\u2013100) CVH. NAFLD was determined by transient elastography measured hepatic steatosis in the absence of other liver diseases and excess alcohol use. Multivariable logistic and restricted cubic spline models were used to assess the associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 3588 participants included (weighted mean age, 48.0\u00a0years; 95% confidence interval [CI] 46.4\u201349.7\u00a0years), 1839 were female (weighted percentage, 51.6%; 95% CI 49.0\u201354.2%) and 1483 were determined to have NAFLD (weighted percentage, 36.5%; 95% CI 33.3\u201339.7%). The weighted mean LE8 score of the study population was 67.9 (95% CI 66.6\u201369.2). After the adjustment of potential confounders, higher LE8 scores were associated with reduced odds of NAFLD (odds ratio [OR] for per 10 score increase, 0.67; 95% CI 0.59\u20130.76) and a nonlinear dose\u2013response relationship was observed. Similar patterns were also identified in the association of health behavior and health factor scores with NAFLD. The inversed association of LE8 score and NAFLD was significantly stronger among younger, Asian, and participants with higher education and income level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LE8 and its subscales scores were negatively associated with the presence of NAFLD in non-linear fashions. Promoting adherence to optimal CVH levels may be beneficial to reduce the burden of NAFLD as well as CVD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-022-03839-0","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T09:02:59Z","timestamp":1671786179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Associations between life\u2019s essential 8 and non-alcoholic fatty liver disease among US adults"],"prefix":"10.1186","volume":"20","author":[{"given":"Lili","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5212-7749","authenticated-orcid":false,"given":"Xiangpeng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"3839_CR1","doi-asserted-by":"publisher","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","volume":"1","author":"EM Brunt","year":"2015","unstructured":"Brunt EM, Wong VW, Nobili V, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1:15080. https:\/\/doi.org\/10.1038\/nrdp.2015.80.","journal-title":"Nat Rev Dis Primers"},{"issue":"10290","key":"3839_CR2","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/s0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet (London, England). 2021;397(10290):2212\u201324. https:\/\/doi.org\/10.1016\/s0140-6736(20)32511-3.","journal-title":"Lancet (London, England)"},{"issue":"3","key":"3839_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM. Non-alcoholic fatty liver disease\u2014a global public health perspective. J Hepatol. 2019;70(3):531\u201344. https:\/\/doi.org\/10.1016\/j.jhep.2018.10.033.","journal-title":"J Hepatol"},{"issue":"1","key":"3839_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"3839_CR5","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"LA Adams","year":"2017","unstructured":"Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138\u201353. https:\/\/doi.org\/10.1136\/gutjnl-2017-313884.","journal-title":"Gut"},{"issue":"2","key":"3839_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","volume":"65","author":"SM Francque","year":"2016","unstructured":"Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol. 2016;65(2):425\u201343. https:\/\/doi.org\/10.1016\/j.jhep.2016.04.005.","journal-title":"J Hepatol"},{"issue":"10","key":"3839_CR7","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/eurheartj\/ehr453","volume":"33","author":"LS Bhatia","year":"2012","unstructured":"Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J. 2012;33(10):1190\u2013200. https:\/\/doi.org\/10.1093\/eurheartj\/ehr453.","journal-title":"Eur Heart J"},{"issue":"4","key":"3839_CR8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1161\/circulationaha.109.192703","volume":"121","author":"DM Lloyd-Jones","year":"2010","unstructured":"Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association\u2019s strategic Impact Goal through 2020 and beyond. Circulation. 2010;121(4):586\u2013613. https:\/\/doi.org\/10.1161\/circulationaha.109.192703.","journal-title":"Circulation"},{"issue":"5","key":"3839_CR9","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/cir.0000000000001078","volume":"146","author":"DM Lloyd-Jones","year":"2022","unstructured":"Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life\u2019s Essential 8: Updating and enhancing the American heart association\u2019s construct of cardiovascular health: a presidential advisory from the American heart association. Circulation. 2022;146(5):e18\u201343. https:\/\/doi.org\/10.1161\/cir.0000000000001078.","journal-title":"Circulation"},{"key":"3839_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ijcard.2016.03.210","volume":"214","author":"N Fang","year":"2016","unstructured":"Fang N, Jiang M, Fan Y. Ideal cardiovascular health metrics and risk of cardiovascular disease or mortality: a meta-analysis. Int J Cardiol. 2016;214:279\u201383. https:\/\/doi.org\/10.1016\/j.ijcard.2016.03.210.","journal-title":"Int J Cardiol"},{"key":"3839_CR11","doi-asserted-by":"publisher","first-page":"603877","DOI":"10.3389\/fcvm.2021.603877","volume":"8","author":"M Liu","year":"2021","unstructured":"Liu M, Kou F, Yang S, Wang S, He Y, Zhang W. Ideal cardiovascular health in the oldest-old and centenarians and its association with disability and health-related quality of life. Front Cardiovasc Med. 2021;8:603877. https:\/\/doi.org\/10.3389\/fcvm.2021.603877.","journal-title":"Front Cardiovasc Med"},{"key":"3839_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.116.004894","author":"TS Polonsky","year":"2017","unstructured":"Polonsky TS, Ning H, Daviglus ML, et al. Association of cardiovascular health with subclinical disease and incident events: the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2017. https:\/\/doi.org\/10.1161\/jaha.116.004894.","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"3839_CR13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1161\/circulationaha.122.060911","volume":"146","author":"DM Lloyd-Jones","year":"2022","unstructured":"Lloyd-Jones DM, Ning H, Labarthe D, et al. Status of cardiovascular health in US adults and children using the American heart association\u2019s new \u201clife\u2019s essential 8\u201d metrics: prevalence estimates from the National Health and Nutrition Examination Survey (NHANES), 2013 through 2018. Circulation. 2022;146(11):822\u201335. https:\/\/doi.org\/10.1161\/circulationaha.122.060911.","journal-title":"Circulation"},{"issue":"4","key":"3839_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.amjmed.2020.09.023","volume":"134","author":"E Oni","year":"2021","unstructured":"Oni E, Ogunmoroti O, Allen N, et al. Life\u2019s simple 7 and nonalcoholic fatty liver disease: the multiethnic study of atherosclerosis. Am J Med. 2021;134(4):519\u201325. https:\/\/doi.org\/10.1016\/j.amjmed.2020.09.023.","journal-title":"Am J Med"},{"key":"3839_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.2061","author":"C Van Dongen","year":"2022","unstructured":"Van Dongen C, Paik JM, Harring M, et al. Sarcopenia, healthy living, and mortality in patients with chronic liver diseases. Hepatol Commun. 2022. https:\/\/doi.org\/10.1002\/hep4.2061.","journal-title":"Hepatol Commun"},{"issue":"1","key":"3839_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/hep4.1614","volume":"5","author":"LR DeCoste","year":"2021","unstructured":"DeCoste LR, Wang N, Palmisano JN, et al. Adherence to ideal cardiovascular health metrics is associated with reduced odds of hepatic steatosis. Hepatol Commun. 2021;5(1):74\u201382. https:\/\/doi.org\/10.1002\/hep4.1614.","journal-title":"Hepatol Commun"},{"key":"3839_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8050610","author":"EH Jang","year":"2019","unstructured":"Jang EH, Chang Y, Ryu S, et al. Cardiovascular health metrics in the development and regression of nonalcoholic fatty liver disease: a cohort study. J Clin Med. 2019. https:\/\/doi.org\/10.3390\/jcm8050610.","journal-title":"J Clin Med"},{"key":"3839_CR18","unstructured":"Centers for Disease Control and Prevention. National health and nutrition examination survey. National center for health statistics. 2022. https:\/\/www.cdc.gov\/nchs\/nhanes\/index.htm. Accessed 26 Aug 2022."},{"issue":"9596","key":"3839_CR19","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/s0140-6736(07)61602-x","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England). 2007;370(9596):1453\u20137. https:\/\/doi.org\/10.1016\/s0140-6736(07)61602-x.","journal-title":"Lancet (London, England)"},{"issue":"9","key":"3839_CR20","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.jand.2018.05.021","volume":"118","author":"SM Krebs-Smith","year":"2018","unstructured":"Krebs-Smith SM, Pannucci TE, Subar AF, et al. Update of the Healthy Eating Index: HEI-2015. J Acad Nutr Diet. 2018;118(9):1591\u2013602. https:\/\/doi.org\/10.1016\/j.jand.2018.05.021.","journal-title":"J Acad Nutr Diet"},{"issue":"6","key":"3839_CR21","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/hep.32207","volume":"75","author":"E Vilar-Gomez","year":"2022","unstructured":"Vilar-Gomez E, Nephew LD, Vuppalanchi R, et al. High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. Hepatology. 2022;75(6):1491\u2013506. https:\/\/doi.org\/10.1002\/hep.32207.","journal-title":"Hepatology"},{"key":"3839_CR22","unstructured":"National Cancer Institute. Healthy eating index SAS code. 2022. https:\/\/epi.grants.cancer.gov\/hei\/sas-code.html. Accessed 31 Aug 2022"},{"key":"3839_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.12.029","author":"E Vilar-Gomez","year":"2021","unstructured":"Vilar-Gomez E, Vuppalanchi R, Mladenovic A, et al. Prevalence of high-risk Nonalcoholic Steatohepatitis (NASH) in the United States: results from NHANES 2017\u20132018. Clin Gastroenterol Hepatol. 2021. https:\/\/doi.org\/10.1016\/j.cgh.2021.12.029.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"3839_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","volume":"17","author":"MS Siddiqui","year":"2019","unstructured":"Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(1):156-163.e2. https:\/\/doi.org\/10.1016\/j.cgh.2018.04.043.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"3839_CR25","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/liv.14060","volume":"39","author":"H Liu","year":"2019","unstructured":"Liu H, Yao Y, Wang Y, et al. Ideal cardiovascular health metrics and the risk of non-alcoholic fatty liver disease: a cross-sectional study in northern China. Liver Int. 2019;39(5):950\u20135. https:\/\/doi.org\/10.1111\/liv.14060.","journal-title":"Liver Int"},{"issue":"2","key":"3839_CR26","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.atherosclerosis.2012.07.042","volume":"224","author":"J Liu","year":"2012","unstructured":"Liu J, Musani SK, Bidulescu A, et al. Fatty liver, abdominal adipose tissue and atherosclerotic calcification in African Americans: the Jackson heart study. Atherosclerosis. 2012;224(2):521\u20135. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2012.07.042.","journal-title":"Atherosclerosis"},{"issue":"2","key":"3839_CR27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.atherosclerosis.2015.04.009","volume":"240","author":"K Ozturk","year":"2015","unstructured":"Ozturk K, Uygun A, Guler AK, et al. Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men. Atherosclerosis. 2015;240(2):380\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.04.009.","journal-title":"Atherosclerosis"},{"issue":"1 Suppl","key":"3839_CR28","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-64. https:\/\/doi.org\/10.1016\/j.jhep.2014.12.012.","journal-title":"J Hepatol"},{"issue":"9","key":"3839_CR29","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691\u2013705. https:\/\/doi.org\/10.1136\/gutjnl-2020-320622.","journal-title":"Gut"},{"issue":"8","key":"3839_CR30","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","volume":"65","author":"N Katsiki","year":"2016","unstructured":"Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65(8):1109\u201323. https:\/\/doi.org\/10.1016\/j.metabol.2016.05.003.","journal-title":"Metabolism"},{"key":"3839_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.etap.2019.03.006","volume":"69","author":"V Quagliariello","year":"2019","unstructured":"Quagliariello V, Coppola C, Mita DG, et al. Low doses of Bisphenol A have pro-inflammatory and pro-oxidant effects, stimulate lipid peroxidation and increase the cardiotoxicity of Doxorubicin in cardiomyoblasts. Environ Toxicol Pharmacol. 2019;69:1\u20138. https:\/\/doi.org\/10.1016\/j.etap.2019.03.006.","journal-title":"Environ Toxicol Pharmacol"},{"issue":"3","key":"3839_CR32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1042\/cs20040174","volume":"108","author":"S Kofler","year":"2005","unstructured":"Kofler S, Nickel T, Weis M. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci (Lond). 2005;108(3):205\u201313. https:\/\/doi.org\/10.1042\/cs20040174.","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"3839_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","volume":"20","author":"V Quagliariello","year":"2021","unstructured":"Quagliariello V, De Laurentiis M, Rea D, et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. 2021;20(1):150. https:\/\/doi.org\/10.1186\/s12933-021-01346-y.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"3839_CR34","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","volume":"53","author":"Y Sumida","year":"2018","unstructured":"Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD\/NASH. J Gastroenterol. 2018;53(3):362\u201376. https:\/\/doi.org\/10.1007\/s00535-017-1415-1.","journal-title":"J Gastroenterol"},{"issue":"6","key":"3839_CR35","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"EASL-EASD-EASO","year":"2016","unstructured":"EASL-EASD-EASO. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388\u2013402. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.004.","journal-title":"J Hepatol"},{"issue":"10","key":"3839_CR36","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41575-021-00477-7","volume":"18","author":"JV Lazarus","year":"2021","unstructured":"Lazarus JV, Anstee QM, Hagstr\u00f6m H, et al. Defining comprehensive models of care for NAFLD. Nat Rev Gastroenterol Hepatol. 2021;18(10):717\u201329. https:\/\/doi.org\/10.1038\/s41575-021-00477-7.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"3839_CR37","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","volume":"160","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Corey KE, Lim JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2021;160(3):912\u20138. https:\/\/doi.org\/10.1053\/j.gastro.2020.11.051.","journal-title":"Gastroenterology"},{"issue":"5","key":"3839_CR38","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264-1281.e4. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.036.","journal-title":"Gastroenterology"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03839-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03839-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03839-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T09:06:17Z","timestamp":1671786377000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03839-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3839"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03839-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"assertion":[{"value":"22 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NHANES is conducted by the Centers for Disease Control and Prevention (CDC) and the National Center for Health Statistics (NCHS). The NCHS Research Ethics Review Committee reviewed and approved the NHANES study protocol. All participants signed written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interest that pertain to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"616"}}